Share
.webp)
.webp)
.webp)
.webp)
Geno Germano
Orbital Therapeutics, a company advancing RNA medicines to improve global health, has appointed Geno Germano to its Board of Directors.
With 35 years of experience in the biopharma and life sciences industries, Mr. Germano brings extensive leadership in drug development and commercialization across multiple therapeutic areas.
Mr. Germano most recently served as President and CEO of Elucida Oncology, a clinical-stage company focused on nanoparticle drug conjugates. Previously, he was President of Intrexon (now Precigen), a leader in synthetic biology, and has held senior leadership roles at several prominent biopharmaceutical companies. As Group President of Pfizer’s Global Innovative Pharmaceutical Business, he managed a US$20 billion portfolio and oversaw the late-stage development of numerous drug candidates. Mr. Germano also served as President of Wyeth U.S., where he led its pharmaceutical and women’s healthcare divisions, and as Executive Vice President of its vaccines division. Earlier in his career, he held senior roles at Johnson & Johnson.
In addition to his leadership experience, Mr. Germano has served on the boards of multiple biopharma organizations and public companies, including Zoetis, Bioverativ, and The Medicines Company. He currently serves on the boards of Sage Therapeutics and Precision Biosciences. Mr. Germano holds a B.S. from the Albany College of Pharmacy and Health Sciences.
